MAPK14 and non-small cell lung carcinoma: Treatment with the MAPK14 inhibitor SB203580 (0.5 μM) in the co-culture system effectively inhibited the activation of ADAM17 and minimized the increase in CX3CL1 concentration in co-cultured media conferred by NSCLC cells, indicating phosphorylated MAPK14 is a master effector in the activation of ADAM17 (Figure 6H-I).